Weight loss effect of glucagon-like peptide-1 mimetics on obese/overweight adults without diabetes: A systematic review and meta-analysis of randomized controlled trials

Journal of Diabetes

Volumn 7, Issue 3, 2015, Pages 329-339

  Zhang, Fang ^a   Tong, Yuzhen ^a   Su, Na ^a   Li, Yi ^a   Tang, Lizhi ^a,b   Huang, Li ^a   Tong, Nanwei ^a  

^a SICHUAN UNIVERSITY   (China)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Glucagon like peptide 1 mimetics; Meta analysis; Non diabetes; Obesity; Weight loss

Indexed keywords

ADIPONECTIN; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; LIRAGLUTIDE; TRIACYLGLYCEROL; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; GLUCAGON RECEPTOR;

ADULT; ARTICLE; BODY MASS; COCHRANE LIBRARY; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; EMBASE; HUMAN; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INFORMATION RETRIEVAL; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MEDLINE; META ANALYSIS; NAUSEA AND VOMITING; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE; WEIGHT CHANGE; WEIGHT REDUCTION; AGONISTS; BIOMIMETICS; DRUG EFFECTS; OVERWEIGHT; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADULT; BIOMIMETICS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; OBESITY; OVERWEIGHT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, GLUCAGON; WEIGHT LOSS;

EID: 84928211618     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/1753-0407.12198     Document Type: Article

References (57)

1. National Heart L, and Blood Institute in cooperation with The National Institute of Diabetes and Digestive and Kidney Diseases. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. The evidence report. NIH Publication 1998; NO. 98-4083.
2. Snow V, Barry P, Fitterman N, Qaseem A, Weiss K, for the Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Pharmacologic and surgical management of obesity in primary care: A clinical practice guideline from the American College of Physicians. Ann Intern Med. 2005; 142: 525-531.
3. Wu Y. Overweight and obesity in china. BMJ. 2006; 333: 362-363.
4. Lund A, Knop FK, Vilsbøll T. Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: Differences and similarities. Eur J Intern Med. 2014; 25: 407-414.
5. Sharma MD, Garber AJ. What is the best treatment for prediabetes? Curr Diab Rep. 2009; 9: 335-341.
6. Garber AJ, Handelsman Y, Einhorn D etal. Diagnosis and management of prediabetes in the continuum of hyperglycemia - when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. Endocr Pract. 2008; 14: 933-946.
7. Klonoff DC, Buse JB, Nielsen LL etal. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin. 2008; 24: 275-286.
8. Perreault L, Pan Q, Mather KJ etal. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: Results from the diabetes prevention program outcomes study. Lancet. 2012; 379: 2243-2251.
9. Moutzouri E, Tsimihodimos V, Rizos E, Elisaf M. Prediabetes: To treat or not to treat? Eur J Pharmacol. 2011; 672: 9-19.
10. Neeland IJ, Turer AT, Ayers CR etal. Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. JAMA. 2012; 308: 1150-1159.
11. Robinson JR, Niswender KD. What are the risks and the benefi ts of current and emerging weight-loss medications? Curr Diab Rep. 2009; 9: 368-375.
12. Moreno JL, Willett KC, Desilets AR. Exenatide as a novel weight loss modality in patients without diabetes. Ann Pharmacother. 2012; 46: 1700-1706.
13. Ottney A. Glucagon-like peptide-1 receptor agonists for weight loss in adult patients without diabetes. Am J Health Syst Pharm. 2013; 70: 2097-2103.
14. Kieffer JT, Habener FJ. The glucagon-like peptides. Endocr Rev. 1999; 20: 876-913.
15. Zhang F, Tang X, Cao H etal. Impaired secretion of total glucagon-like peptide-1 in people with impaired fasting glucose combined impaired glucose tolerance. Int J Med Sci. 2012; 9: 574-581.
16. Monami M, Dicembrini I, Marchionni N, Rotella CM, Mannucci E. Effects of glucagon-like peptide-1 receptor agonists on body weight: A meta-analysis. Exp Diabetes Res. 2012; 2012: 672658. doi: 10.1155/2012/672658.
17. Defronzo RA, Abdul-Ghani M. Type 2 diabetes can be prevented with early pharmacological intervention. Diabetes Care. 2011; 34: S202-209.
18. Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: Systematic review and meta-analyses of randomised controlled trials. BMJ. 2012; 344: d7771.
19. Preferred reporting items for systematic reviews and meta-analyses (prisma) statement website. 2009. Available from: http://www.prisma-statement.org/ (accessed 1 August 2014).
20. World Health Organization. Obesity and overweight. Available from: http://www.who.int/mediacentre/factsheets/fs311/en/. Updated March 2013. (accessed 1 August 2014).
21. The Expert Committee on The Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003; 26: 3160-3167.
22. World Health Organization/International Diabetes Federation. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: Report of a WHO/IDF consultation. 2006.
23. Zhu Q, Tong Y, Wu T, Li J, Tong N. Comparison of the hypoglycemic effect of acarbose monotherapy in patients with type 2 diabetes mellitus consuming an eastern or western diet: A systematic meta-analysis. Clin Ther. 2013; 35: 880-899.
24. The Cochrane Collaboration. Cochrane handbook for systematic reviews of interventions. 2011. Available from: http://www.cochrane.org/training/cochrane-handbook. (accessed 1 August 2014).
25. Kelly AS, Bergenstal RM, Gonzalez-Campoy JM, Katz H, Bank AJ. Effects of exenatide vs. Metformin on endothelial function in obese patients with pre-diabetes: A randomized trial. Cardiovasc Diabetol. 2012; 11: 64. doi: 10.1186/1475-2840-11-64.
26. Astrup A, Rössner S, Van Gaal L etal. Effects of liraglutide in the treatment of obesity: A randomised, double-blind, placebo-controlled study. Lancet. 2009; 374: 1606-1616.
27. Elkind-Hirsch K, Marrioneaux O, Bhushan M, Vernor D, Bhushan R. Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metabol. 2008; 93: 2670-2678.
28. Jensterle Sever M, Kocjan T, Pfeifer M, Kravos NA, Janez A. Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin. Eur J Endocrinol. 2013; 170: 451-459.
29. Dushay J, Gao C, Gopalakrishnan GS etal. Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes. Diabetes Care. 2012; 35: 4-11.
30. Kim SH, Abbasi F, Lamendola C etal. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care. 2013; 36: 3276-3278.
31. Rosenstock J, Klaff LJ, Schwartz S etal. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabetes Care. 2010; 33: 1173-1175.
32. Wadden TA, Klaff LJ, Klein S etal. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The scale maintenance randomized study. Int J Obes. 2013; 37: 1443-1451.
33. Astrup A, Rössner S, Van Gaal L, Rasmusen M. Authors' reply. Lancet. 2010; 375: 552-553.
34. Gillani SR, Singh BM. An audit of glucagon-like peptide 1 (glp-1) agonist use in morbidly obese people without diabetes. Diabet Med. 2013; (Suppl.)1: 82.
35. Niswender K, Pi-Sunyer X, Buse J etal. Weight change with liraglutide and comparator therapies: An analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes Obes Metab. 2013; 15: 42-54.
36. Ktout M, Zhu H, Rutsky J etal. Effect of glp-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: Results of a systematic meta-analysis and meta-regression. Am J Hypertens. 2013; 27: 130-139.
37. Schwartz EA, Koska J, Mullin MP, Syoufi I, Schwenke DC, Reaven PD. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus. Atherosclerosis. 2010; 212: 217-222.
38. van Bloemendaal L, Sten Kulve J, la Fleur SE, IJzerman RG, Diamant M. Effects of GLP-1 on appetite and body weight: Focus on the central nervous system. J Endocrinol. 2014; 221: T1-T16.
39. Holst JJ, Deacon CF. Is there a place for incretin therapies in obesity and prediabetes? Trends Endocrinol Metab. 2013; 24: 145-152.
40. Tong J, Sandoval DA. Is the GLP-1 system a viable therapeutic target for weight reduction? Rev Endocr Metab Disord. 2011; 12: 187-195.
41. Chelikani PK, Haver AC, Reidelberger RD. Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats. Am J Physiol Regul Integr Comp Physiol. 2005; 288: R1695-1706.
42. Verdich C, Flint A, Gutzwiller JP etal. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab. 2001; 86: 4382-4389.
43. Madsbad S. The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications. Diabetes Obes Metab. 2014; 16: 9-21.
44. Nauck MA, Kemmeries G, Holst JJ, Meier JJ. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes. 2011; 60: 1561-1565.
45. Buse JB, Rosenstock J, Sesti G etal. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomised, parallel-group, multinational, open-label trial (lead-6). Lancet. 2009; 374: 39-47.
46. Jelsing J, Vrang N, Hansen G, Ravn K, Tang-Christensen M, Knudsen LB. Liraglutide: Short lived effect on gastric emptying-long lasting effects on body-weight. Diabetes Obes Metab. 2012; 14: 531-538.
47. Osaka T, Endo M, Yamakawa M, Inoue S. Energy expenditure by intravenous administration of glucagon-like peptide-1 mediated by the lower brainstem and sympathoadrenal system. Peptides. 2005; 26: 1623-1631.
48. Flint A, Raben A, Ersbøll AK, Holst JJ, Astrup A. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes Relat Metab Disord. 2001; 25: 781-792.
49. Van Can Maastricht J, Sloth B, Jensen CB etal. Effects of liraglutide on appetite, ad libitum energy intake, 24-hour energy expenditure and substrate oxidation in obese non-diabetic adults: A randomized, placebo-controlled, incomplete crossover trial (abstract 259-p). The Obesity Society Meeting, San Antonio, TX. Available from: www.obesity.org/obesity2012. (Accessed December 2012).
50. Hayes MR, Kanoski SE, Alhadeff AL, Grill HJ. Comparative effects of the long-acting glp-1 receptor ligands, liraglutide and exendin-4, on food intake and body weight suppression in rats. Obesity. 2011; 19: 1342-1349.
51. European Medicines Agency. Novo nordisk, summary of product characteristics. Victoza. 2010.
52. European Medicines Agency. Eli Lilly & Co., Summary of Product Characteristics. Byetta. 2011.
53. Sauer N, Schulze zur Wiesch C, Reining F, Rohani Z, Aberle J. Off-label glp-1 agonist treatment in 43 non-diabetic patients: Are weight loss and treatment tolerance equally promising outside of clinical trials? Diabetol Stoffwechsel. 2013; 18: P287.
54. Timofte L, Stratmann B, Quester W, Bojită MT, Tschoepe D. Exenatide and liraglutide - side effects. Comparative clinical study. Farmacia. 2013; 61: 837-844.
55. Del Prato S, Bianchi C, Miccoli R, Penno G. Pharmacological intervention in prediabetes: Considering the risks and benefits. Diabetes Obes Metab. 2007; 9 (Suppl 1): 17-22.
56. Astrup A, Carraro R, Finer N etal. NN8022-1807 Investigators. Safety, tolerability, and sustained weight loss over 2 years with the once-daily human glp-1 analog, liraglutide. Int J Obes. 2012; 36: 843-854.
57. Dunican KC, Desilets AR, DeBellis RJ. Long-term pharmacotherapy for overweight and obesity: A review of sibutramine, orlistat and rimonabant. Am J Lifestyle Med. 2007; 1: 367-385.